Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 BillionThe Motley Fool • 07/16/26
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug24/7 Wall Street • 07/16/26
Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big TakeoverInvestors Business Daily • 07/16/26
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?The Motley Fool • 07/16/26
Medicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027Benzinga • 07/16/26
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billionProactive Investors • 07/16/26
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?Investors Business Daily • 07/16/26
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain tractionCNBC • 07/16/26
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsPRNewsWire • 07/16/26
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reportsReuters • 07/15/26
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study DataZacks Investment Research • 07/15/26
It's been three months since Lilly launched its obesity pill. Most people are taking Novo's pill instead.WSJ • 07/15/26
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD SurgeZacks Investment Research • 07/14/26
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?The Motley Fool • 07/14/26